Podcasts about rp2

Kejaksaan Negeri (Kejari) Batam menerima titipan uang pengganti sebesar Rp2,8 miliar dan USD 14.276 dari tersangka kasus dugaan korupsi terkait pengelolaan Penerimaan Negara Bukan Pajak (PNBP) pada jasa pemanduan dan penundaan kapal di Pelabuhan Batam, Kepulauan Riau.

ASN di Polewali Mandar tersandung kasus korupsi anggaran Dinas Kesehatan tahun 2023. Nilai kerugian negara ditaksir mencapai Rp2,1 miliar. Dana yang seharusnya digunakan untuk layanan kesehatan justru diselewengkan demi kepentingan pribadi.

Bank Indonesia mencatat kredit konsumsi tumbuh 9,4% per Februari 2025, mencapai Rp2.208,5 triliun. Kredit multiguna menjadi pendorong utama dengan Rp1.265 triliun, diikuti KPR Rp799,8 triliun, dan kredit kendaraan Rp143,1 triliun. Secara keseluruhan, kredit perbankan naik 9% menjadi Rp7.684 triliun.

Memasuki bulan suci Ramadan, harga beberapa kebutuhan pokok di pasar tradisional terpantau mulai merangkak naik.Di Pasar Tradisional Badak, Pandeglang, Banten, harga telur ayam telah mengalami kenaikan sejak sepekan lalu. Dari yang semula Rp28.000 per kilogram, kini naik Rp2.000 menjadi Rp30.000 per kilogram.Sementara itu, harga minyak bersubsidi Minyakita masih belum sesuai dengan Harga Eceran Tertinggi (HET) yang ditetapkan pemerintah, yaitu Rp15.700 per liter. Para pedagang justru menjualnya dengan harga lebih tinggi, mencapai Rp18.000 per liter.

BKPK Kemenkes: Cek Kesehatan Gratis Setara dengen Rp2 juta Per Orang | Retret Kepala Daerah, Wamendagri: Dilakukan 21-28 Fabruari | Pemkot Solo Pantau Ribuan pangkalan LPG di Wilayahnya

Di tahun 1864, seorang teman lama Karl Marx meninggal dunia. Sang teman ini, memberikan Karl Marx warisan sebesar £820. Jumlah uang tersebut sangat besar di zaman itu. Saya menghitung dengan kalkulator inflasi dan nilainya setara dengan £133 ribu saat ini – kalau dirupiahkan artinya mencapai sekitar Rp2,3 miliar. Marx yang hidupnya rada-rada susah karena bergantung dari karier jurnalis, penulis dan juga sumbangan dari rekan-rekannya, tentu akhirnya mendapatkan duit lebih. Rumahnya di London dapat perabotan baru, anak-anaknya dibelikan hewan peliharan berupa anjing, kucing dan burung. Marx bersama keluarganya bahkan ngambil liburan 3 minggu di wilayah Ramsgate, Kent – ini wilayah pesisir paling terkenal di Inggris pada abad ke-19. Walaupun saat liburan itu, si Marx rada-rada ngenes karena dia kena bisul di selangkangan yang bikin dirinya lebih banyak tinggal di penginapan. Anyway, di momen dapat durian runtuh duit warisan ini, Marx menulis sepucuk surat untuk pamannya di Belanda yang adalah seorang pengusaha kaya di daerah Zaltbommel. Ia menyebutkan bahwa dirinya juga spending beberapa dari duit itu di pasar saham. Yes, Marx main saham, walaupun, kisah ini masih jadi perdebatan karena para sejarawan belum menemukan bukti Marx main saham. Hanya dibuktikan dari kata-kata dia di surat ini. Nah, pertanyaannya, siapa sosok paman Marx yang kaya raya, kerap ngasih duit juga untuk dia, bahkan Marx sering numpang di rumah pamannya itu? Well, namanya adalah Lion Philips, dan yes, ada nama Philips di sana. Faktanya, dia adalah kakek dari Gerard dan Anton Philips – dua orang yang mendirikan Philips Electronics – perusahaan elektronik terkemuka di dunia yang kita kenal dengan slogan “terus terang terang terus”!

Kasus dugaan kriminalisasi terhadap guru honorer Supriyani di Baito, Konawe Selatan menyulut kemarahan publik. Kasus ini terus bergulir dan bahkan mengungkap banyak hal tentang realita masyarakat kecil saat berhadapan dengan hukum. Awalnya, perkara berpusat pada tudingan bahwa Supriyani menganiaya siswanya, anak dari Ajun Inspektur Dua Wibowo Hasyim, Kanit Intel Polsek Baito. Tuduhan dibantah Supriyani dan sejumlah saksi dari sekolah. Kasus berlanjut ke pengadilan hingga sekarang, Supriyani pun sempat ditahan. Dalam perkembangannya, terkuak permintaan uang damai sebesar Rp50 juta dan Rp2 juta kepada Supriyani, yang diduga melibatkan personel kepolisian. Tujuh anggota polisi kemudian diperiksa, dua di antaranya berlanjut ke pemeriksaan etik. Kasus ini juga diwarnai insiden penembakan mobil bekas Camat Baito, Sudarsono usai menghadiri sidang Supriyani. Sudarsono dicopot dari jabatannya sebagai camat, diduga karena aktif membantu Supriyani. Sedemikian kompleksnya kasus ini bergulir, bagaimana mengawal agar guru Supriyani bisa mendapatkan keadilan? Apa dampak kasus ini terhadap wajah penegakan hukum ke depan? Kita bincangkan bersama Kuasa Hukum Guru Honorer Supriyani, Andre Darmawan dan Direktur Jaringan Gusdurian, Alissa Wahid. *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Kelas menengah di Indonesia berada di titik yang mengkhawatirkan. Badan Pusat Statistik (BPS) mencatat 9,48 juta warga kelas menengah Indonesia turun kelas dalam lima tahun terakhir. Berdasarkan definisi Bank Dunia, kelas menengah adalah kelompok masyarakat dengan pengeluaran antara Rp2,04 juta hingga Rp9,9 juta per bulan. Merujuk data terbaru BPS tersebut, artinya banyak dari mereka yang kini berubah status menjadi kelas menengah rentan. Kelompok ini kerap digambarkan dengan istilah miris, misalnya, "generasi makan tabungan" atau "dari zona nyaman ke zona makan". Jika terus dibiarkan, maka struktur ekonomi Indonesia bakal makin timpang. Kelas menengah yang sebelumnya menopang ekonomi nasional, bakal tergerus dan menambah jumlah kelompok rentan. Kondisi ini menjadi PR besar dan harus dijawab oleh kepemimpinan baru di bawah Prabowo-Gibran. Apa saja dampak yang bakal muncul jika jumlah kelas menengah terus menurun? Opsi kebijakan apa saja yang bisa ditempuh pemerintahan Prabowo-Gibran untuk mengatasi persoalan ini? Kita bincangkan bersama Guru Besar Ekonomi Universitas Padjadjaran (Unpad) Prof. Arief Anshory Yusuf dan Putu Rusta Adijaya, Peneliti Bidang Ekonomi The Indonesian Institute, Center for Public Policy Research (TII). *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Bismillah, Sahabat, amal shalih yang dilakukan di 10 hari pertama Dzulhijjah sangat dicintai Allah. Jangan lewatkan prime time ini untuk totalitas beramal shalih!Shalat, haji, qurban, puasa, dzikir, sedekah?Tambah terus amalnya, segera masuk ke pintu kebaikan manapun.Atau, bisa juga gabung sekarang di program “Terbaik di Dzulhijjah”.Di mana insyaa Allah kita bisa meraih pahala dari:1. Berbagi pangan berbuka puasa sunnah Dzulhijjah.2. Festival Semarak Qurban & Takbir.3. Berbagi daging qurban mentah & olahannya.4. Berbagi hidangan Tasyrik.5. Produksi tas kulit qurban & aksesorisnya untuk guru.6. Berbagi buku doa untuk dzikir.Dengan total dana program Rp2.665.000.000.Sampaikan sedekah terbaik kita melalui:CIMB Niaga Syariah8600-1383-1800Bank Syariah Indonesia1111811567a.n. Muhajir Peduli Indonesia#TerbaikdiDzulhijjahIkuti Muhajir Project Pedulidi Facebook & Instagram@muhajirprojectpeduli

Bismillah, Sahabat, hasil pengoptimalan manfaat kulit hewan qurban yang kita ikhtiarkan di hari-hari terbaik Dzulhijjah tahun lalu, alhamdulillah telah dirasakan di bulan mulia ini.Atas izin Allah, lebih dari 400 tas kulit qurban yang diproduksi beberapa bulan lalu telah sampai kepada ratusan guru di berbagai wilayah Indonesia.Membersamai mereka dalam aktivitas-aktivitas keilmuan, salah satunya mengajar para santri dan penghafal Al-Qur'an.Semoga limpahan keberkahan tersebut tidak hanya kita rasakan di bulan mulia ini, namun juga di bulan-bulan ke depan.Di tahun ini, ayo kembali berjuang dalam rangkaian amal shalih “Terbaik di Dzulhijjah”. Rangkaian aktivitasnya meliputi:1. Berbagi pangan Dzulhijjah, termasuk pangan untuk buka puasa sunnah Dzulhijjah.2. Festival Semarak Qurban & Takbir.3. Berbagi daging qurban mentah & olahannya.4. Berbagi hidangan Tasyrik.5. Produksi tas kulit qurban & aksesorisnya untuk guru-guru kita.6. Berbagi buku doa untuk dzikir.Dengan total dana program sebesar Rp2.665.000.000.Jadikan Dzulhijjah kita spesial, penuh pahala berlipat ganda. Sampaikan sedekah terbaik kita melalui:CIMB Niaga Syariah8600-1383-1800Bank Syariah Indonesia1111811567a.n. Muhajir Peduli Indonesia#TerbaikdiDzulhijjahIkuti Muhajir Project Pedulidi Facebook & Instagram@muhajirprojectpeduli

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Kementerian Pertanian menyerahkan paket bantuan pertanian pascabanjir dan program regular pertanian senilai lebih dari Rp 410 Miliar. Kementan juga menyerahkan subsidi pupuk subsidi senilai lebih dari Rp2,5 Triliun.

Headline News MetroTV Edisi 2069 kali ini membahas beredar informasi tentang adanya dugaan pungutan liar di SMK Negeri 1 Depok. Dalam video yang beredar, setiap siswa dikenakan uang pungutan sebesar Rp2,8 juta.

Wisata Luar Angkasa, Sensasi atau Prestasi? Oleh. Firda Umayah(Kontributor NarasiPost.Com) Voice over talent: Dewi Nasjag NarasiPost.Com-Sobat, perusahaan pariwisata swasta milik Sir Richard Branson sukses menggelar layanan perdana wisata luar angkasa pada 29 Juni 2023. Dikutip dari inet.detik.com pada 1 Juli 2023, perusahaan dirgantara asal Inggris itu berhasil melakukan misi penerbangan dengan empat penumpang ke ruang suborbital. Perjalanan selama 90 menit itu lantas diberi nama Virgin Galactic 01.Penumpang akan merasakan sensasi melayang seperti astronaut saat di kabin pesawat. Wah, sepertinya seru banget, ya? Untuk dapat menikmati perjalanan luar angkasa ini, tentu saja butuh dana yang tidak sedikit, ya, Sobat. Kalian harus menyediakan Rp2,1 miliar untuk uang muka dari total biaya sebesar Rp6,4 miliar. Wow, fantastis, bukan? Dengan harga itu, wisatawan akan dimanjakan dengan pemandangan planet bumi dari ruang angkasa dan tempat menginap yang eksklusif seperti di Spaceport America di New Mexico yang dikenal supermewah. Tiket yang dijual dari penyelenggara wisata ini juga dibatasi hanya sampai 1.000 orang saja, lo. Meskipun wisatawan nanti mencoba wisata luar angkasa, bukan berarti wisatawan lantas disebut sebagai astronaut. Sebab, untuk menjadi astronaut, ada kriteria tersendiri yang harus dipenuhi. Kapitalisme dan Wisata Luar Angkasa Tak dapat dimungkiri, kecerdasan manusia ditambah kecanggihan teknologi telah menghasilkan berbagai inovasi yang dapat mempermudah manusia menjalani aktivitas. Inovasi ini juga kaya akan sarana hiburan yang dianggap mampu mengusir kejenuhan manusia dari permasalahan hidup, salah satunya adalah wisata luar angkasa. Wisata ini diklaim dapat mengusir penatnya hidup karena hanya berada di lingkungan bumi saja. Hem, kira-kira benar enggak, ya? Naskah selengkapnya: https://narasipost.com/teenager/07/2023/wisata-luar-angkasa-sensasi-atau-prestasi/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipost

Pekerjaan rumah untuk menyehatkan industri fintech peer-to-peer (P2P) lending tampak masih panjang. Syarat ketentuan ekuitas minimal Rp2,5 miliar pada 4 Juli 2023 belum bisa dipenuhi puluhan pelaku usaha P2P lending. Beberapa di antaranya bahkan masih memiliki ekuitas negatif.n Otoritas Jasa Keuangan (OJK) pun telah mematok ekuitas minimal naik menjadi Rp7,5 miliar pada 4 Juli 2024 dan Rp12,5 miliar pada 4 Juli 2025. Sanksi pembatasan kegiatan mengancam mereka yang belum memenuhi syarat ekuitas. Sementara, buat perusahaan-perusahaan yang berpotensi kolaps dalam waktu dekat akan dimerger berdasarkan pasal 129 UU No. 4/2023 tentang Pengembangan dan Penguatan Sektor Keuangan. Di luar persoalan modal, regulator juga perlu terus membenahi beberapa titik penting industri ini, seperti kualitas credit scoring atau skor kredit perusahaan teknologi finansial. Harapannya, penyelenggara fintech terus meningkatkan kualitas risk management, kepatuhan, dan tata kelola dan bertumbuh dengan sehat. #p2plending #fintech #ojk #modal --- Support this podcast: https://podcasters.spotify.com/pod/show/broad-cash/support

Ngadu ke DPR, Yasonna Minta Tambahan Anggaran Kemenkumham jadi Rp2,2 Triliun | Indeks Kepercayaan Industri Bulan Mei Melambat | Korsel: Peluncuran Roket Korut Pelanggaran Berat terhadap Resolusi PBB *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Com receio dos impactos da CPMI dos atos antidemocráticos, cujo requerimento deve ser lido pelo presidente do Congresso, Rodrigo Pacheco (PSD-MG), amanhã, o governo Lula resolveu abrir o cofre e prometeu um jeton de R$ 5 milhões a R$ 7 milhões a cada deputado federal integrante da base governista, informa a Folha. Esse dinheiro seria repassado por meio de emendas tipo RP2, aquelas obras tocadas pelos ministérios. Assim, os deputados precisariam apenas mandar um ofício gentil solicitando que as pastas executem obras diretamente em suas bases parlamentares. É um esquema ainda mais obscuro que o orçamento secreto. “Segundo deputados, o ministro Waldez Góes (Integração e Desenvolvimento Regional) procurou parlamentares nas últimas semanas para falar sobre a liberação das emendas”, destaca o jornal. “Segundo relatos feitos à reportagem, nas últimas semanas integrantes do governo passaram a ser pressionados para acelerar a liberação da verba, num contexto em que a frágil base de sustentação do Executivo petista começará a ser testada no Congresso”, acrescenta. Em outros tempos, isso teve um nome: mensalão. Inscreva-se e receba a newsletter:  https://bit.ly/2Gl9AdL Confira mais notícias em nosso site:  https://oantagonista.uol.com.br/ https://crusoe.uol.com.br/ Acompanhe nossas redes sociais:  https://www.fb.com/oantagonista​ https://www.twitter.com/o_antagonista ​https://www.instagram.com/o_antagonista https://www.tiktok.com/@oantagonista_oficial No Youtube deixe seu like e se inscreva no canal: https://www.youtube.com/c/OAntagonista

Jokowi : Angka Stunting Menurun di 2022, Target Tahun 2024 Harus Tercapai | Apdesi Akui Usulan Perpanjangan Masa Jabatan Kepala Desa Rawan Dipolitisasi | Kerusakan infrastruktur akibat perang di Ukraina capai Rp2 kuadriliun *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Pemerintah Kota (Pemko) Pekanbaru sudah menyiapkan anggaran Rp2,8 Miliar untuk atlet berprestasi

Pemerintah Kota (Pemko) Pekanbaru sudah menyiapkan anggaran Rp2,8 Miliar untuk atlet berprestasi

Pemerintah dan Badan Anggaran DPR menyepakati kenaikan target penerimaan perpajakan di tahun 2023 menjadi Rp2.021,2 triliun.

英國科學家說，一種使用普通病毒來感染和破壞癌細胞的新療法在早期人體試驗中效果顯著。 其中，一名病人的癌症徹底消失，其他患者的腫瘤也縮小了。 該藥物通過對唇皰疹病毒的弱化版進行改造，並用它殺死腫瘤。 唇皰疹病毒是一種單純皰疹病毒。 接下來還需要進行更大規模和更長時間的研究，但專家說，這種病毒注射療法最終會給更多晚期癌症患者提供一條生命線。 這種直接把病毒注射到腫瘤里的療法以兩種方式攻擊癌症 - 通過侵入癌細胞並使其破裂，以及通過啟動免疫系統。 作為試驗的一部分，大約有40名患者參與了治療。 一些患者只接受了名為RP2的單獨病毒注射; 其他一些人在病毒注射之外還接受另一種癌症藥物納武利尤單抗的治療。 在法國巴黎舉行的醫學大會上所發表的這一研究結果顯示：在9名只接受RP2注射治療的患者中，有3人腫瘤縮小，30名接受聯合治療的人中有7 人病症似乎改善，而且疲倦等副作用一般都很輕微。 領導該試驗的研究人員對BBC表示，在包括對食道癌以及一種罕見眼癌等一系列晚期癌症的治療中，所看到的治療效果“真的非常不錯”。 事實上，這並不是科學家第一次使用病毒來對付癌症。 幾年前，英國全民健康系統NHS已經批准了一種基於感冒病毒的療法，叫做T-Vec，用它來治療晚期皮膚癌。 此外，100年前科學家就發現病毒可以幫助治療癌症，但如何安全有效地使用它們則一直是一種挑戰。 如今，這一令人鼓舞的發現則可能改變癌症治療的進程。 發表這一研究的貝克博士說，“這一新病毒療法在小規模早期試驗中顯示出令人鼓舞的效果 -- 現在我們需要更多研究來瞭解它效果到底有多好。 研究顯示，結合多種治療方法是更有效的策略，而像這樣的病毒療法可以成為我們戰勝癌症工具包的一部分。 ”

Sebagai platform fintech, Modalku menyediakan layanan pendanaan digital, peminjam (UMKM yang berpotensi) bisa mendapatkan pinjaman modal usaha tanpa jaminan hingga Rp2 miliar yang didanai oleh pendana platform (individu atau institusi yang mencari alternatif investasi) melalui pasar digital. Simak DSPodcast by DailySocial episode kali ini bersama Co-founder dan CEO Modalku Reynold Wijaya.

The dudes sit down with famed 'Package from China' YouTuber Wicked Gamer & Collector! They discuss all things that are good, including the latest handhelds, all eight of Wicked's channels, each one more sinister than the last, and how to properly pronounce 'PowKiddy'!Get Wicked at https://allmylinks.com/wickedpromotionWatch this episode on YT shortly at https://youtube.com/RetroHandheldsPurchase links-PowKiddy V90: https://s.click.aliexpress.com/e/_DDuok5VShargeek Retro 35W GaN charger: https://amzn.to/3fgJOuHAnbernic Win600: https://s.click.aliexpress.com/e/_DkIOVzZAnbernic 353V: https://s.click.aliexpress.com/e/_Ddb9dnZRetroid Pocket 3: https://s.click.aliexpress.com/e/_Dmket4PAYN Odin: https://www.indiegogo.com/projects/odin-the-ultimate-gaming-handheld/x/27409825#/http://retro-handhelds.combooking@retro-handhelds.com | contact@retro-handhelds.comPO Box: Retro Handhelds 345 W Carlisle St. # 714 Mooresville, IN, 46158, USASubscribe to a Premium Membership on Discord or Patreon for extra perks and support the cast!https://discord.gg/RetroHandheldshttps://patreon.com/RetroHandheldsRH Theme song by Jim Gray (http://ourghosts.bandcamp.com)Please be aware that this description may contain affiliate links. By purchasing something through the affiliate link, RH may earn a small commission of the sale at no extra cost to you.

Welcome to Season 2! Stubbs and Thor discuss the future of retro gaming and how FPGA is taking over, the new Retroid Pocket 1 Plus (prototype). Then they dive into all the shenanigans going on in their lives, the lengths Stubbs goes to play Star Ocean his way, Thor's first emulation experience, Sony's replaced PS Now service, and lastly Stubbs has a shameful admission (don't tell Eems!).http://retro-handhelds.comhttps://patreon.com/RetroHandheldsbooking@retro-handhelds.com | contact@retro-handhelds.comPO Box: Retro Handhelds 345 W Carlisle St. # 714 Mooresville, IN, 46158, USARH Theme song by Jim Gray (http://ourghosts.bandcamp.com)

Thor and Stubbs hangout with OnionOS dev Jim Gray! They talk all things Miyoo, Onion, Union, and all things that are fun. This is more or less a "review" and "good time". OH, it's also a giveway! Yes, tell Thor the hidden code and you'll receive a free Miyoo Mini!Watch this episode on YT at https://youtu.be/ZdDPEw9H_zACheck OnionOS out at GitHub - jimgraygit/Onion: Stock OS overhaul for Miyoo MiniBuy a Mini at https://s.click.aliexpress.com/e/_9HchTNFind more at https://Retro-Handhelds.comChat with us at https://discord.gg/RetroHandheldsJoin our Patreon at https://patreon.com/RetroHandhelds (subscribe to get a free copy of RESET Collection for Android and go next level in RH community content)Intro music and audio mastering by JimGrayNote that this description may contain affiliate links. By clicking on an affiliate link and buying something, Retro Game Corps may earn a small commission of the sale at no extra cost to you.This podcast is for entertainment and educational purposes only.#MiyooMini #Miyoo #RetroGaming

Stubbs and Thor are joined by Youtuber Victor Lemini to discuss the state of the Retro Handheld market, the Ayn Odin (of course), Anbernic RG552, RP2+, and the infamous Powkiddy X18S! Stubbs gets mad, Thor laughs at him, and Cheeto Steve ruins yet another line of handhelds that were just this close to perfect!Check Victor's channel out at https://www.youtube.com/victorieminiWatch this episode on YouTube at https://www.youtube.com/RetroHandheldsX18S Compatibility Sheet: http://tinyurl.com/X18SGameSettingsFind more at https://Retro-Handhelds.comChat with us at https://discord.gg/RetroHandheldsJoin our Patreon at https://patreon.com/RetroHandhelds (subscribe to get a free copy of RESET Collection for Android and go next level in RH community content)Intro music and audio mastering by JimGray

Stubbs and Thor deep dive into the AYN Odin Pro and reveal their thoughts, conclusions and concerns! They also present a performance showcase of games from GameCube to PS2 and decide if the Odin is "The One".Buy one here: https://igg.me/at/yLg321qZuMg/x/27409825#/ (affiliate link to support our podcast)Watch this episode on YouTube at https://youtu.be/xlTwzbnU1mEOdin Compatibility Sheet: http://tinyurl.com/Odin-845aFind more at https://Retro-Handhelds.comChat with us at https://discord.gg/RetroHandheldsJoin our Patreon at https://patreon.com/RetroHandhelds (subscribe to get a free copy of RESET Collection for Android and go next level in RH community content, covering all of your Odin needs!)Thanks to our RH Patrons! 24Block, FlatFootFox, Acorns, Axryn, Cebion, Chthonox, Cognative, CrazyDave, CrippNipp, DamienWright, DoggPogg, Eems, Empleh_doG, JaLanimal, Jav,Juicy, LiquidDivide, me038372, MegaBarrakuda, Morc, MrFaust, pkegg, plaidman, RavenMage, RetroGameCorps, DollerBill, SetsunaGuerrero, Scott, Thor, TotallyTerry, Transience8985, VolfaniBros, Wesmo, WIP, Wonderfool!BRB Theme song by ChooshEditing by JimGrayPhotography by AxrynVideo editing by Stubbs

Stubbs (joined by Thor, Axryn and even a guest appearance by Choosh, and Russ from Retro Game Corps!) unboxes and sets up an AYN Odin Pro for over 4 hours! They try out the launcher, setup a frontend, and dive into game testing for PS2, GC, 3DS, DC, PSP (10X Resolution!), N64, Android apps, GamePass, Stadia. They also go over the feel of the device, and compare the screen and feel to the RG552, RP2+, Switch Lite, and others. Odin deep dive review on the way, stay tuned!Note: Spotify version of this episode is not working.Watch this bonus episode on YouTube!Find more at https://Retro-Handhelds.comChat with us at https://discord.gg/RetroHandheldsThanks to our Patrons! Join at https://patreon.com/RetroHandhelds and check the $5 tier to get a free copy of RESET Collection Frontend.Scott's Odin Compatibility Sheet: http://tinyurl.com/Odin-845a BRB Theme song by Choosh, RH intro song by Peter Arvidson Music, Animation and thumbnail by Kei, Editing by Stubbs 

Stubbs and Thor invite Scott the Natchosloth possum onto the show! They celebrate the launch of the AYN Odin handheld, and Scott delivers an in-depth presentation on just how deep the Odin rabbit hole goes. He talks community culture, the origin story, and finally reveals if he is actually Taki's alt account. It gets weird, folks! Enjoy this tell-all interview with one of the internet's most elusive and beloved possums!Find Scott on Taki's discord at: https://discord.gg/pZNazYscQDContribute to Scott's Odin Compatibility sheet at: https://tinyurl.com/Odin-845aBRB theme music by ChooshRH theme music by Peter Arvidson MusicAudio edited by JimGrayVideo edited by StubbsWatch this episode on YouTube!More fun at Retro-Handhelds.comIf you're enjoying this content, we have a Patreon!

Thor and Stubbs welcome back Russ from Retro Game Corps! The gang dives into WebRcade, RP2+, RG552, Aya Neo Next, Miyoo Mini, GPD XP, Analogue Pocket, MiSTer FPGA, Xbox Dev mode, and why onions aren't gross! Just another day in retro handheld life!Watch this episode on YouTube!Find Russ at https://YouTube.com/c/RetroGameCorpsThanks to our Patrons! Join at https://patreon.com/RetroHandheldsChat with us (and Russ) at https://discord.gg/RetroHandheldsMore episodes at https://brb-gaming.comFill in your game tests at https://retro-handhelds.com (look for the spreadsheets)Theme song by ChooshThumbnail Artwork by KeiBRB Logo by ChooshAudio editing by StubbsVideo editing by KeiPatron outro song by Peter Arvidson

Its New Years Eve! Stubbs & Rapid99 each give their Top 5 Handhelds of 2021, go over community reveals, a giveaway, and deep dive into their favorite games of 2021. Also device comparisons, and a hangout with the crew! Happy New Years all! See you in 2022!Watch this episode on YouTube at https://youtu.be/gKKZKqRJ3PwThanks to our Patrons! Join at https://patreon.com/RetroHandheldsChat with us at https://discord.gg/RetroHandheldsMore episodes at https://brb-gaming.comCheck out Rapid99 (Cyberphile) on YouTube at https://www.youtube.com/cyberphileIntro/Outro background music - "This is Christmas" by Scott Holmes Music https://freemusicarchive.org/music/Scott_Holmes/christmas-background-music/this-is-christmas-1Theme song by Choosh

It's Christmas Day! Thor and Stubbs do a year end roundup of 2021 and give their hopes and predictions for 2022 handhelds. Also, A20 Lineage, RG552 CFW, RP2+ info, and more! This is one you won't want to miss!Watch this episode on YouTube!Thanks to our Patrons! Join at https://patreon.com/RetroHandheldsChat with us at https://discord.gg/RetroHandheldsMore episodes at https://brb-gaming.comIntro/Outro background music - "This is Christmas" by Scott Holmes Music https://freemusicarchive.org/music/Scott_Holmes/christmas-background-music/this-is-christmas-1BRB Theme song by Choosh

Stubbs and Thor deep dive into the Retroid Pocket 2 Plus and give their thoughts, test performance, discuss upcoming CFW of Lineage, and offer a full review!Buy yours at https://goretroid.com (non affiliate link)Enter your game settings at https://tinyurl.com/RP2PlusGameSettingsWatch this episode on YouTube!Chat with us at https://discord.gg/RetroHandheldsMore episodes at https://brb-gaming.comTheme song by ChooshThanks to our Patrons! Join at https://patreon.com/RetroHandhelds

The dudes welcome a lil dude, and dive right into rg552, RP2+, X18s, Miyoo, Matrix Unreal 5, FF14 Endwalker, and a bunch of other nonsense you'll just need to hear for yourself!Theme song by ChooshThanks to our Patrons! Join at Patreon.com/RetroHandheldsChat with us at https://discord.gg/RetroHandheldsWatch this episode on YouTube!

Thor, Stubbs, and Axryn host an RH community night AMA with a slew of community guests! This episode was almost lost as Stubbs didn't get his audio recorded, luckily he was crazy enough to re-record his parts from scratch. What ensues is pure madness, with a dash of reveals, GOTM, GOTY news, and even a sing-a-long! Lets go!Thanks to our patrons!Join our Patreon at https://patreon.com/RetroHandheldsJoin our Discord at https://discord.gg/RetroHandheldsBRB Theme by Choosh 

YouTuber JimRPG joins the gang on a wild ride through the handheld world, their favorite black friday deals, and many other topics we won't spoil for you with this silly summary. Happy turkey times, everyone!JimRPG on the internet: YouTube: https://youtube.com/c/JimRPGTwitter: @JimRPGDiscord: https://discord.gg/gXs9JhUtrkYouTube2: https://youtube.com/channel/UCWgiqwQCTOhXdq1JbEfJ63ATheme song by ChooshOur Discord: https://discord.gg/RetroHandhelds

After taking some time to process and reflect on the dense narrative clod of RP2, we're finally back with a new chapter. And what a chapter it is!Open up your body and mind to Ernest's ping-pong prose as he pilots your unthinking telebot corpse through a hailstorm of revelations and plot twists which some critics have suggested he could have done with spreading out a bit. Important Links

Thor and Stubbs get personal with YouTuber and Hype Train Conductor Taki Udon. We ask our most burning questions about Odin, RP2+, RP3 (and many more), and take a deep dive into the realities of making some of your favorite devices (and their delays)!Taki:https://youtube.com/c/TakiUdonhttps://discord.gg/pZNazYscQDSezuko's X18S Mods:https://youtu.be/HY9j-I6IpeMRetro Handhelds & BRB:https://discord.gg/RetroHandheldshttps://Retro-Handhelds.comRetroid:https://discord.gg/4AJGykQEaHBRB Theme song by Choosh

We're celebrating 1 year of being a community in Retro Handhelds! We talk memories, games, and compare our favorite handhelds (Odin, RP2, RGB10 Max, 351, all the things) ! Ft. Stubbs, Thor, Victoria (Silverdusk), Eems, FlatFootFox, Rapid99 (Cyberphile), Rickinbsb, RetroGameCorps (Russ Crandall), and Sandusky!Theme song by ChooshJoin us at https://discord.gg/RetroHandhelds

Thor and Stubbs sit down with Russ Crandall from Retro Game Corps and ask him all of Discord and Reddit's questions about various handhelds. He compares, contrasts, and offers his hot takes on various retro devices that have been hitting the market the last few years.Visit Russ's YouTube at https://www.youtube.com/c/RetroGameCorpsJoin our discord server at https://discord.gg/RetroHandheldsBRB theme by Choosh

In this episode Stubbs and Thor discuss the new Retro Handhelds community, unveil an Android OS/Launcher, catch up on the haps and games they aren't playing, and share about close calls with the underworld.BRB Theme song by ChooshDiscord: https://discord.gg/RetroHandhelds

For one reason or another retro is back, but has it ever left? Today TheeNerdyDad and Eems talk about some of the concepts and creators, big and small, that drive the retro community today.Discord: https://discord.gg/RetroHandheldsEditing by Jav.BRB theme song by Choosh.Intro/outro song: Runescape - Sea Shanty 2 by High Tide Lofihttps://gamechops.com/sea-shanty-2-high-tide-lofi/Content creators mentioned:TheeNerdyDad - https://twitch.tv/theeNerdyDadRetroGM - retrogm.comPositron Plays - https://www.youtube.com/c/PositronPlaysMahko - https://www.youtube.com/channel/UC5FYpo9lFqK1Y7wqjPuANFwElliot of The Retro Future - https://www.youtube.com/channel/UCefAbzsWZE4uXU-mqQMrr4QTito of Macho Nacho Productions - https://www.youtube.com/channel/UC4CsqctrGOn4NTz09sAhXwQTaki Udon - https://www.youtube.com/channel/UCKF5151a6yAooOILrYTvfJgRetroDodo - https://www.youtube.com/user/TechBoomTVGames Done Quick - https://www.twitch.tv/gamesdonequickTwitch Plays Pokemon - https://www.twitch.tv/twitchplayspokemon 

In this episode Stubbs, Choosh, Thor and Eems welcome developer Franco Catrin of the RetroX emulation app, as he dishes on all things retro, from PC-Engine to the RP2, RetroX origins, future plans, other projects, and his ongoing love of CRT's and guitar.Get RetroX here: https://www.retrox.tv/ Intro/outro song: Mario & Chill - Game Over by Helyenthttps://gamechops.com/mario-and-chill/BRB theme song by ChooshEditing by JavDiscord: https://discord.gg/RetroHandhelds

In this Game Boy focused episode, host Eems, along with StubbornPixel, and Thor, interview Game Boy modder EsotericSean about the rise of EsotericMods, and his transition into Game Boy game development, along with general nerding out about Retroid Pocket and other handhelds.EsotericMods: https://instagram.com/esotericmodsDiscord: https://discord.gg/RetroHandheldsBRB theme song by Choosh!Intro/outro song: Fairy Sh*t by teamteamworkhttps://soundcloud.com/teamteamworkEditing by Jav

Eems and StubbornPixel welcome guest Taki Udon for this retro handheld focused episode. We interview Taki about his YouTube channel as he shares his beginnings, being a dad, war stories, Retroid Pocket adventures, and what the future holds.Taki Udon Channel https://youtube.com/c/TakiUdonDiscord: https://discord.gg/RetroHandheldsBRB theme song by Choosh!Intro/outro song: Colorful Flowers by Tokyo Music Walker https://soundcloud.com/user-356546060Editing by Jav 

StubbornPixel, Choosh, and Thor introduce BRB Gaming. They discuss what it was like playing games growing up and how that compares to gaming as adults with responsibilities, new and old game achievements, and Retroid Pocket 2 custom firmware development.Editing and theme song by ChooshDiscord: https://discord.gg/RetroHandhelds

Introduction! Thanks for the warm and overwhelming support on the return! Chapter 007 Recap Parzival has an epiphany that his home school planet of Ludus is actually the resting place of the Tomb of Horrors. After exploiting away to travel there without zero credits, he manages to find the entrance and makes his way in, ready for the perils that lie ahead. Chapter 0008 Summary With the help of a map from the Tomb of Horrors module, Parzival makes his way through the treacherous tomb avoiding traps and monsters and collecting a heavy amount of gold pieces along the way. He's eventually confronted by Acererak who challenges him to a best 2 out of 3 game of Joust, the classic arcade game. Parzival bests Acererak winning the copper key along with a clue to the first gate but before he's able to leave the Tomb of Horrors, he's stopped short of the entrance by a mysterious figure who making their way inside as well… Chapter 0008 Narrative  Parzival uses his map to navigate through the ToH and avoid most of the traps and monsters Levels up like a few types of classes; monster xp vs GP xp; gp xp converts to OASIS credits He eventually makes his way to the Pillared Throne Room where he sees a throne and Acereak sitting there which is a break from the D&D module The voices inside our heads here - what did you hear when you read the booK? "Not horses," he replied, stepping away from his throne. "Birds." The rules to win a copper key, best two out of three. Of course, Parzival had honed his skills over time and credits Aech as it was his favorite (and former) game used to settle asinine pop culture disputes, but did you ever take issue with just how good Wade/Parzival was at everything? I've seen some of the negative criticism from people who didn't paritcularly like the novel and it's a go-to for a lot of those people. Parzival gets his arse handed to him in match #1; but then asks to play on the other side in order to win games 2 and 3 After the second win, Acererak pounds on the side of the cabinet smashing into pixles and graciously congratulates Parzival before taking the form of Anorak. Anaorak hands him the copper key, and Parzival notice two lines of text etched into the key reading, “What you seek lies hidden in the trash on the deepest level of Daggorath.” He immediately knows exactly what this hints refers to and has a hunch that he needs to travel to Middletown, a re-creation of Halliday's hometown as a boy. There, in Halliday's old home, he would find a "Dungeons of Daggorath" game and somehow that would lead him to the first gate to use the copper key on. All he needed to do now was get out of the Tomb of Horrors and make his way immediately there, but just as he was leaving the tomb, he is confronted by the silhouette of another avatar… The Pop!  Reference: “My flashlight reached into the darkness ahead, flickering off the damp stone walls. My surroundings made me feel like I was in a low-budget sword-and-sorcery flick, like Hawk the Slayer or The Beastmaster.” Hawk the Slayer (1980) Directed by Terry Marcel Starring Jack Palance, John Terry, Bernard Bresslaw Movie Synopsis Trivia The Beastmaster (1982) Directed by Don Coscarelli Starring Marc Singer, Tanya Roberts, Rip Torn, and John Amos Movie Synopsis Trivia Excalibur (1981) Reference: “When I put on the suit of magical armor, it shrank to fit my avatar perfectly. Its gleaming chrome appearance reminded me of the bad-ass armor worn by the knights in Excalibur.” Directed by John Boorman Starring Nigel Terry, Helen Mirren, Nicholas Clay, Cherie Lunghi, a bunch of other guys, but more importantly Liam Neeson and Patrick Stewart!   Movie Synopsis Trivia Joust (1982) Reference: “He waved a skeletal hand at his throne. There was a brief flash of light, accompanied by a transformation sound effect (which I was pretty sure had been lifted from the old Super Friends cartoon). ” Developed by Williams Electronics Designed by John Newcomer Game premise. Released on nearly every game system, ever. World record holder and meeting John Newcomer in 2018. The All New Super Friends Hour (1977 - 1978) Reference: “He waved a skeletal hand at his throne. There was a brief flash of light, accompanied by a transformation sound effect (which I was pretty sure had been lifted from the old Super Friends cartoon). ” Produced by Hanna-Barbera and aired on ABC Based on DC Characters Premise of the show and characters Street Fighter 2 (1991) Reference: “The last time we'd played (Joust), I'd rubbed his nose in defeat so mercilessly that he'd flipped out and vowed never to play me again. Since then, we'd used Street Fighter II to settle our disputes.” Developed by Capcom Produced by Yoshiki Okamoto Trivia Reference: “It suddenly occurred to me just how absurd this scene was: a guy wearing a suit of armor, standing next to an undead king, both hunched over the controls of a classic arcade game. It was the sort of surreal image you'd expect to see on the cover of an old issue of Heavy Metal or Dragon magazine.” Heavy Metal (1977 - 1992) (1992 - 2014) (2014 - Present) Founder: Leonard Mogel Premise Trivia Dragon Magazine (1976 - 2007) Created by TSR Premise Trivia Star Wars: “The Throne Room and End Title” (1977) Reference: “I recognized the music. It was the last track from John Williams's original Star Wars score, used in the scene where Princess Leia gives Luke and Han their medals (and Chewbacca, as you may recall, gets the shaft).” Directed by George Lucas Stars Mark Hammill, Harrison Ford, Carrie Fisher, Alec Guiness, Peter Cushing, Anthony Daniels, Peter Mayhew, Kenny Baker, James Earl Jones, Trivia Dungeon and Dragons Cartoon (1982 - 1985) Reference: “And before I could ask what I was supposed to do next, or where I could find the first gate, his avatar vanished in a flash of light, accompanied by a teleportation sound effect I knew was lifted from the old '80s Dungeons & Dragons cartoon.” Co-produced by Marvel Productions and TSR Voices of Willie Aames, Don Most, Katie Leigh, Adam Rich, Peter Cullen (Optimus Prime), Frank Welker (Megatron), and a number of others Premise Trivia Lord of the Rings (elvish language - Quenya) Reference: “Dagorath was a word in Sindarin, the Elvish language J. R. R. Tolkien had created for The Lord of the Rings. The word dagorath meant “battle,” but Tolkien had spelled the word with just one “g,” not two." Started in 1910 Primarily made up of Finnish, but has some Latin, Greek, Welsh, and older Germanic languages as well. Quenya, Sindarin, and the origins Trivia "May It Be" - Enya, 2002 The Tomb of Horrors (1978) Written by Gary Gygax For characters level 10-14 Premise The Traps The Sphere of Annihilation  Magic Items +1 Flaming sword A gem of seeing +1 Ring of Protection +3 Full Plate mail armor Bag of Holding Areas of Interest Chapel of Evil  Pillared Throne Room  The Scoreboard iTunes Review: 5 stars! "Keep it coming. RP2 is on the way!" - JDR2000 Patreon: Danny P - Crystal Key Holder 3-2-1 Contact! Instagram, Twitter, YouTube, and Twitch: @TheBasementRPO Facebook: /TheBasementRPO Patreon: www.patreon.com/TheBasementRPO TeePublic: http://tee.pub/lic/mjtTM-nrguo